BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center® (RGC) have discovered rare genetic mutations in the GPR75 gene associated with protection against obesity.

tab32, the dental industry’s #1 cloud-based, full-service technology platform, today announced the appointment of three top industry experts to its advisory board.

Following a media article published yesterday, ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, indicated it continues ongoing discussions with the European Commission regarding VLA2001, Valneva’s inactivated COVID-19 vaccine candidate.

Ferring Pharmaceuticals announced that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman.

Hansa Biopharma AB will publish its interim report for January-June 2021 at 8:00 CET on July 15, 2021.

Philip Morris International Inc. (PMI) (NYSE: PM) announced today it has entered into an agreement to acquire Fertin Pharma A/S (Fertin Pharma), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems.

Targovax ASA announces the appointment of Dr Lone Ottesen, MD, PhD as Chief Development Officer. She will take a leading role in driving the clinical programs forward.

Kintara Therapeutics, Inc. today announced topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083.

Adverum Biotechnologies, Inc. today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective immediately.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced that new long-term efficacy and safety data based on interim analyses at 109 weeks from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the PPMD 2021 Annual Conference.